JAY W. MARKS, M.D.; RICHARD A. BAUM, M.D.; RUSSELL F. HANSON, M.D.; THEODORE HERSH, M.D.; N. C. HIGHTOWER Jr, M.D.; HAGOP MEKHJIAN, M.D.; ROBERT A. SCHAEFER, M.D.; ROGER D. SOLOWAY, M.D.; JOHNSON L. THISTLE, M.D.; FRED B. THOMAS, M.D.; MALCOLM P. TYOR, M.D.
During the National Cooperative Gallstone Study, therapy with chenodiol, 750 or 375 mg/d, for 2 years resulted in confirmed, complete gallstone dissolution in 14% and 5% of patients, respectively, and partial dissolution (> 50%) in 27% and 18%. The present study was done to determine the frequency with which complete dissolution occurs in patients having partial dissolution of gallstones who receive additional therapy. Eighty-six of one hundred thirty-eight eligible patients continued to receive 750 mg/d (61 patients) or 375 mg/d (25 patients) of chenodiol for 1 year. Patients whose oral cholecystogram at the end of the year showed further (> 50%) dissolution continued to receive chenodiol (28 patients at 750 mg/d and 11 patients at 375 mg/d) for a second year (total duration of therapy, 4 years). A final oral cholecystogram was taken at the end of the fourth year. Complete dissolution occurred in 23% and 16% of patients receiving chenodiol, 750 or 375 mg/d, respectively, for an additional 1 or 2 years.
MARKS JW, BAUM RA, HANSON RF, et al. Additional Chenodiol Therapy After Partial Dissolution of Gallstones with Two Years of Treatment. Ann Intern Med. 1984;100:382–384. doi: 10.7326/0003-4819-100-3-382
Download citation file:
Published: Ann Intern Med. 1984;100(3):382-384.
Biliary Disorders, Gastroenterology/Hepatology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use